Login / Signup

Exploration of Pyrido[3,4- d ]pyrimidines as Antagonists of the Human Chemokine Receptor CXCR2.

Max Van HoofSandra ClaesKatrijn BoonTom Van LoyDominique ScholsWim DehaenSteven De Jonghe
Published in: Molecules (Basel, Switzerland) (2023)
Upregulated CXCR2 signalling is found in numerous inflammatory, autoimmune and neurodegenerative diseases, as well as in cancer. Consequently, CXCR2 antagonism is a promising therapeutic strategy for treatment of these disorders. We previously identified, via scaffold hopping, a pyrido[3,4- d ]pyrimidine analogue as a promising CXCR2 antagonist with an IC 50 value of 0.11 µM in a kinetic fluorescence-based calcium mobilization assay. This study aims at exploring the structure-activity relationship (SAR) and improving the CXCR2 antagonistic potency of this pyrido[3,4- d ]pyrimidine via systematic structural modifications of the substitution pattern. Almost all new analogues completely lacked the CXCR2 antagonism, the exception being a 6-furanyl-pyrido[3,4- d ]pyrimidine analogue (compound 17b ) that is endowed with similar antagonistic potency as the original hit.
Keyphrases
  • cell migration
  • structure activity relationship
  • endothelial cells
  • multiple sclerosis
  • oxidative stress
  • papillary thyroid
  • molecular docking
  • single molecule
  • induced pluripotent stem cells